Author:incardatheraadmin

InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team

Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in Atrial Fibrillation in Q3 2021; Data Expected 2H 2022 Appointment of Angela Wang as CFO Strengthens...

Grace Colón Participates on Panel Hosted by Women in Bio (WIB)

YWIB-San Francisco Bay Area: Spring Into STEM–Extraordinary Leaders Transforming the Future of STEM The San Francisco Bay Area Chapter of Young Women In Bio is thrilled to bring together an extraordinary group of leaders at the forefront of science. Join us for an inspiring discussion with...